Amylin Plans Byetta sNDA Submission For Expanded Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
The sNDA for use of exenatide in patients on thiazolidinediones will likely be submitted to FDA in mid-2006.
You may also be interested in...
Amylin To Celebrate New Year With New Byetta Claim For Use With TZDs
Phase III monotherapy data are expected in late 2007, partner Lilly tells “The Pink Sheet” DAILY.
Amylin To Celebrate New Year With New Byetta Claim For Use With TZDs
Phase III monotherapy data are expected in late 2007, partner Lilly tells “The Pink Sheet” DAILY.
Lilly/Amylin’s Byetta Type 2 Diabetes Therapy To Launch June 1
Amylin will put 325 reps behind exenatide, in addition to a Lilly sales force. The firms will target 60,000 physicians in first six months. First-in-class gut hormone follows approval of Amylin’s diabetes therapy Symlin in March.